Piribedil

SKU: orb1225204

Description

Piribedil is an antiparkinsonian agent andpiperazine derivative which acts as a D2 and D3 receptor agonist. It also has α2-adrenergic antagonist properties(In Vitro):Piribedil (0-160 μM, 7 days) specifically inhibits MLL1 methyltransferase activity and selectively suppresses MLL-r cell proliferation.Piribedil (0-160 μM, 4 days) selectively decreases the H3K4 methylation in MLL-r cells (THP-1 and MV4;11), by disturbing the MLL1-WDR5 interaction.Piribedil (0-160 μM, 4 days) induces cell-cycle arrest, apoptosis and differentiation in MLL-r cells (THP-1 and MV4;11).(In Vivo):Piribedil (intraperitoneal injection, 5, 15, 40 mg/kg ) alleviates the L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease.Piribedil (oral gavage, 4-5 mg/kg, daily for 2 weeks) increases locomotor activity and reversal of motor deficits in adult common marmosets.Piribedil (oral gavage, 150 mg/kg, daily for 21 days) inhibits MLL-r tumor growth and decreases the expression of MLL1 target genes in MV4;11 tumor xenografts.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 3605-01-4
• MW: 298.34
• Purity: >98% (HPLC)
• Formula: C₁₆H₁₈N₄O₂
• SMILES: C1(N2CCN(CC3=CC4=C(C=C3)OCO4)CC2)=NC=CC=N1
• Target: Adrenergic Receptor
• Solubility: Soluble in chloroform, DMSO, Ethanol, Water

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Piribedil | ET 495 | ET-495 | ET495 | EU 4200

Quick Database Links

Gene Symbol

Adrenergic Receptor